Best Pharma and BioTech News Podcasts (2025)

1
Industry Shifts: Mergers, Regulations, and Biotech Breakthroughs 8:20

Play Pause

10h ago8:20

8:20

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of transformative events reshaping the landscape of healthcare, from strategic mergers and regulatory shifts to groundbreaking advancements in drug development.Let's begin with a monu…

1
Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast) 12:32

19h ago12:32

12:32

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2025年10月31日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。本次要闻: 本期要闻——第三季度并购交易回暖；诺华收购Avidity后并购火力依旧；韩美制药肥胖症候选药物展现三期试验潜力；英伟达合作推动礼来人工智能计划；礼来收购Adverum强化基因疗法布局。Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-MQMX2YHSAVHBTJFR4RAEAYNFNQ/Playlist: on.sound…

1
Scrip's Five Must-Know Things - Nov. 4, 2025 13:00

13h ago13:00

13:00

Audio roundup of selected biopharma industry content from Scrip over the business week ended October 31, 2025. In this episode: third quarter dealmaking picks up; Novartis still has M&A firepower even after Avidity acquisition; Hanmi’s obesity contender shows Phase III promise; NVIDIA partnership progresses Lilly’s AI plans; and Lilly builds gene t…

1
How Pharma Can Build Trust and Reach Patients in Health Marketplaces (Sponsored) 11:21

1d ago11:21

11:21

The healthcare marketing landscape is evolving fast — shaped by regulatory shifts, patient empowerment, and the rise of digital health marketplaces. In this episode of The Top Line, sponsored by Havas Media Network, host Chris Hayden sits down with Holly Dunn, Managing Partner of Performance at Havas Media Network, to explore how pharma brands can …

1
Precision Oncology and HIV Prevention Breakthroughs 7:18

1d ago7:18

7:18

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of fascinating advancements and strategic movements that are shaping the landscape of drug development and patient care.Starting with a significant milestone in precision oncology, Ch…

1
Week in Review November 1st 33:50

3d ago33:50

33:50

This Week in Review covers 5 episodes from October 27 to October 31, featuring major developments in the pharmaceutical and biotech industries. Episodes included: 1. Pharma Shifts: Dual-Action Obesity Drugs & Regulatory Waves 2. Navigating Pharma's New Frontiers: Breakthroughs and Challenges 3. Gene Therapy Challenges and Regulatory Shifts: Industr…

1
Drug Fix: US FDA Streamlines Biosimilar Development Requirements, Clarifies Inspection Reform 23:20

4d ago23:20

23:20

Pink Sheet Executive Editor Derrick Gingery, Senior Editor Sue Sutter and Editor-in-Chief Nielsen Hobbs consider the impact of the US Food and Drug Administration announcement that a comparative efficacy study is no longer a prerequisite for biosimilar approval (:35), as well as the upcoming guidance stating the interchangeability switching study r…

1
Biotech Graveyard 20:35

4d ago20:35

20:35

Welcome to the Fierce Biotech Graveyard, our annual ritual remembering the biotechs we lost in 2025 and those on the brink. In this episode, Fierce Biotech’s Darren Incorvaia and Gabrielle Masson came together to chat about themes from this year’s graveyard, including a cell therapy mausoleum, some mad science, and Darren’s incredibly dated referen…

1
Decoding Cell Differentiation: How AI Foundation Models Are Reshaping Regenerative Medicine 33:31

4d ago33:31

33:31

What if we could train AI to understand how stem cells become any cell type in the human body? In this episode of the In Vivo Podcast, host David Wild sits down with Micha Breakstone (CEO & Co-founder) and Samantha Dale Strasser (VP of Strategy) from Somite.AI to explore how their company is using foundation models to revolutionize cell therapy dev…

1
How AI Is revolutionizing synthetic biology and biomanufacturing 38:27

4d ago38:27

38:27

Today, I’m joined by Héctor García Martín, a Staff Scientist at Lawrence Berkeley National Laboratory. A pioneer in metabolic engineering and computational biology, Héctor has spent over a decade decoding microbial systems, everything from termite guts to genome-scale flux models, to unlock sustainable biomanufacturing. Now, he’s leading the charge…

1
Pharma Shifts: Dual-Action Obesity Drugs & Regulatory Waves 7:12

4d ago7:12

7:12

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today's focus is on a series of significant advancements that are poised to reshape the landscape of drug development, regulatory standards, and patient care.Eli Lilly has made remarkable strides with its dual-action …

1
Scrip M&A Podcast: What's Next For Dealmaking In The Obesity Space? 36:02

5d ago36:02

36:02

Joseph Haas, senior writer, Scrip, speaks to guest panelists Robert Darwin, partner, Sidley law firm, and Arda Ural, Americas Life Sciences Leader, EY.By Citeline

1
국내 바이오텍 펀딩 활성화를 위해 새로운 촉매제 필요 (Korean-language podcast) 3:42

5d ago3:42

3:42

스톤브릿지벤쳐스의 김현기 상무는 Scrip과의 인터뷰에서 벤처캐피탈의 국내 바이오 투심 회복을 제약하는 요인과 투자 고려사항, 전략 등을 이야기했습니다. https://insights.citeline.com/scrip/leadership/interviews/a-vc-perspective-on-korean-bioventures-new-catalysts-needed-to-jumpstart-activity-Z7IXGZWZVVGKFDPNOWNJJPMWLQ/Playlist: soundcloud.com/citelinesounds/sets/korean-language-biopharma-mini…

1
376: BridgeBio’s great week and Moderna’s unraveling 38:12

5d ago38:12

38:12

Has BridgeBio’s business model worked? How are executives at Moderna dealing with the company’s slump? And who will the hosts dress up as for Halloween? We discuss all that on this week’s episode of the “The Readout LOUD,” STAT’s biotech podcast. We bring on BridgeBio CEO Neil Kumar to discuss the company’s positive Phase 3 readouts and our colleag…

1
14. The NanoPortal platform: Vivani Medical is reimagining how GLP-1s are delivered. 17:21

5d ago17:21

17:21

GLP-1s are transforming the lives of people with diabetes and obesity by improving blood glucose control and promoting substantial weight loss. However, medication adherence is a significant challenge. US-based Vivani Medical, a clinical-stage biopharmaceutical company, is developing miniature implants which are designed to solve this problem. Once…

1
Navigating Pharma's New Frontiers: Breakthroughs and Challenges 6:20

5d ago6:20

6:20

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're exploring a series of significant developments that underscore the rapid evolution within these industries.Starting with one of the major players, Merck, which has been strategically adjusting its focus i…

1
Advancing Innovations for Diabetes and Cardiovascular Disease with Lexicon Pharmaceuticals’ CEO Mike Exton 31:57

6d ago31:57

31:57

In this week’s episode of the Xtalks Life Science Podcast, host Ayesha Rashid, Senior Life Science Journalist at Xtalks.com, welcomes Mike Exton, PhD, CEO of Lexicon Pharmaceuticals, for a conversation about leveraging gene science to develop innovative medicines for serious chronic conditions. Dr. Exton discusses Lexicon’s growing pipeline, which …

1
Gene Therapy Challenges and Regulatory Shifts: Industry Innovations 8:09

6d ago8:09

8:09

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a dynamic landscape of scientific breakthroughs, regulatory shifts, and strategic maneuvers reshaping the industry.BioMarin's recent decision to divest from its hemophilia A gene therapy, Roctavia…

1
Biotech Breakthroughs: Transformative Acquisitions and FDA Milestones 5:25

7d ago5:25

5:25

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into several significant shifts in the industry, marked by scientific advancements, regulatory changes, and strategic corporate maneuvers.Starting with a major acquisition, Novartis has strategical…

1
Novartis' $12B RNA Therapeutics Breakthrough 5:58

8d ago5:58

5:58

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into some of the most significant shifts and strategies shaping our industry.Novartis’s acquisition of Avidity Biosciences for a staggering $12 billion marks a pivotal moment in the pharmaceutical land…

1
Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast) 17:28

9d ago17:28

17:28

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2025年10月24日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。本期聚焦柏林欧洲医学肿瘤学会会议的新成果：Enhertu在早期乳腺癌中的应用；Padcev/Keytruda在膀胱癌领域的突破；Pluvicto的III期试验成功；Trodelvy与Datroway在乳腺癌治疗领域的较量；默克公司为乳腺癌治疗带来新希望。Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-EWX3A6U4TBE5NPDYX…

1
Scrip's Five Must-Know Things - Oct. 27, 2025 17:13

9d ago17:13

17:13

Audio roundup of selected biopharma industry content from Scrip over the business week ended October 24, 2025. In this episode we focus on the most significant results presented at the European Society for Medical Oncology meeting in Berlin: Enhertu in early-stage breast cancer; Padcev/Keytruda in bladder cancer; Phase III wins for Pluvicto; Trodel…

1
Week in Review - October 25, 2025 31:05

10d ago31:05

31:05

This week in review covers 5 episodes from October 20 to October 24, featuring major developments in pharmaceutical and biotech industries including strategic acquisitions, regulatory updates, and clinical trial results. Episodes included: 1. Pharma Innovations: AI's Impact and Strategic Shifts 2. Strategic Acquisitions and AI Revolutionize Pharma …

1
Drug Fix: Another FDA Inspection Reorg, Industry Navigating New DTC Landscape 39:44

11d ago39:44

39:44

Pink Sheet Executive Editor Derrick Gingery, Senior Writer Sarah Karlin-Smith, Senior Editor Sue Sutter and Editor-in-Chief Nielsen Hobbs explain the reasons for the US Food and Drug Administration’s planned “Simple Reform” of its inspection group, including the move away from specialized teams (:44). They also consider industry’s current thinking …

1
Fierce 15: Where are they now? 28:56

11d ago28:56

28:56

This week's episode of "The Top Line" features a discussion about what’s working now in biotech and what isn't. Recorded Oct. 7 at Fierce Biotech Week, this panel featuring leaders from past Fierce 15 winners digs into timelines, partnerships, what's hype, what's signal and how teams are pressure-testing their models in today's market. You'll hear …

1
Pichia pastoris: the microbial protein expression platform you’re probably underestimating 36:02

11d ago36:02

36:02

Today we’re diving into the world of expression systems with Iskandar Dib, of Validogen and we’ll explore the remarkable potential of Pichia pastoris, a methylotrophic yeast that’s revolutionizing pharmaceutical protein production and beyond. From industrial enzymes to biomaterials, food, feed, and diagnostics, Pichia offers a reliable, scalable, a…

1
Pharma Innovations: AI's Impact and Strategic Shifts 6:15

12d ago6:15

6:15

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving deep into a series of significant events that are shaping the future of drug development and patient care.Starting with Merck KGaA, their decision to close the Active Pharmaceutical Ingredient plan…

1
375: Startups push the FDA and biotech booms in North Carolina 29:12

12d ago29:12

29:12

Can Trump take credit for North Carolina's booming biopharma industry? Which drugs could get a shortcut to the market? And who wore a tuxedo to the STAT Summit? We discuss all that and more in the latest episode of "The Readout LOUD." Elaine is out this week, so Adam and Allison dive into the latest news in the life science industry together, inclu…

1
13. Tackling the undruggable: How Beactica's protein degradation platform might transform glioblastoma treatment 31:51

12d ago31:51

31:51

Targeted protein degradation (TPD) represents one of the most transformative advances in drug discovery, with the global market projected to expand from USD 641 million in 2025 to as much as USD 9.85 billion by 2035. This rapidly evolving field enables researchers to eliminate disease-causing proteins rather than merely inhibiting their function, o…

1
Strategic Acquisitions and AI Revolutionize Pharma Landscape 5:34

13d ago5:34

5:34

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of pivotal changes and innovations shaping the industry landscape.Let's begin with a significant acquisition that is resonating across the sector. Alkermes has strategically acquired …

1
At the Heart of Gene Therapy: Lexeo’s R. Nolan Townsend on Genetic Medicines for Cardiovascular Diseases and More 42:07

13d ago42:07

42:07

In this week’s episode of the Xtalks Life Science Podcast, host Ayesha Rashid, Senior Life Science Journalist at Xtalks.com, spoke with R. Nolan Townsend, MBA, CEO of Lexeo Therapeutics, a company developing gene therapies for cardiovascular diseases as well as CNS disorders including Alzheimer’s disease. Lexeo recently announced a partnership to a…

1
Winning Biotech Investors Through Strategic Partnerships and Trial Innovation 45:59

13d ago45:59

45:59

Biotech funding is tougher than ever, but some companies still win big. Join Claire Riches, VP, Clinical Solutions, Citeline and Alistair McDonald, CEO of Worldwide Clinical Trials as they reveal insider strategies for securing investors, navigating partnerships, and turning innovative science into real-world success.View the video series and find …

1
Industry Shifts: Novo Nordisk's Revamp & ADC Breakthroughs 6:13

14d ago6:13

6:13

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the most significant shifts occurring in these industries, touching on strategic restructuring, regulatory milestones, and groundbreaking scientific advancements that are shaping the f…

1
Innovating Autoimmune Treatment with In Vivo CAR-T 9:50

14d ago9:50

9:50

As the potential of in vivo CAR-T therapy moves closer to clinical reality, biotech innovators are reimagining what’s possible in autoimmune disease. With groundbreaking scientific advances and evolving regulatory perspectives, this next generation of cell therapy could redefine how immune-mediated conditions are treated. In this episode, Pete Robi…

1
Transformative Advances in Precision Oncology and ADCs 6:26

15d ago6:26

6:26

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Recent developments in these industries underscore a period of significant scientific progress, regulatory maneuvers, and strategic investments.One notable event was AstraZeneca and Daiichi Sankyo's success at the Eur…

1
How Olon’s fully integrated, end-to-end ADC capabilities drive quality and scale 15:17

15d ago15:17

15:17

Hear experts Matthieu Culié and Alessandro Agosti as they discuss how Olon stands out in a competitive landscape through its fully integrated end-to-end ADC manufacturing expertise, global operations, impurity control and strategic facilities.By Citeline

1
Salesforce’s Mark Sullivan: AI and agentic systems will redefine life sciences (Sponsored) 13:07

16d ago13:07

13:07

Life sciences organizations are facing both intense pressure and extraordinary opportunity, according to Mark Sullivan, president of regulated industries at Salesforce. In a conversation with The Top Line’s Chris Hayden, Sullivan said companies too often operate in “survival mode,” focused on defending margins rather than leading innovation. But wi…

1
Transformative Oncology Breakthroughs and Regulatory Shifts 5:51

16d ago5:51

5:51

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we'll delve into a series of remarkable advancements and strategic movements shaping the landscape of healthcare. Let's start with a recent spotlight on the European Society for Medical Oncology Congress 2025, …

1
Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast) 16:22

16d ago16:22

16:22

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2025年10月17日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。本次要闻: 大型药企仍看好细胞与基因疗法前景；ESMO会议关注焦点；科伦制药TROP2抗体药物偶联物创全球首例；强生预期与白宫政策保持一致；BioFuture会议揭示行业不确定性。Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-ADAR4VZIGRFIFCOMXI7UTZS76U/Playlist: on.soundcloud.com…

1
Scrip's Five Must-Know Things - Oct. 20, 2025 16:29

16d ago16:29

16:29

Audio roundup of selected biopharma industry content from Scrip over the business week ended October 17, 2025. In this episode: big pharma still sees value in cell and gene therapy; what to look out for at ESMO; world first for Kelun’s TROP2 ADC; J&J expects alignment with White House policies; industry uncertainties aired at BioFuture meeting. Sto…

1
Week in review October 18th 2025 30:10

18d ago30:10

30:10

This Week in Review covers episodes from October 14 to October 17, featuring major developments in the pharmaceutical and biotech industries. Episodes included: Biotech Breakthroughs: Partnerships, AI, and Clinical Triumphs Pharma Breakthroughs: Advancing Cancer, Diabetes, and HIV Care Navigating Regulatory Shifts and Strategic Mergers in Biotech R…

1
Drug Fix: US FDA Involved In Astra Zeneca’s Drug Pricing Deal, DOJ’s Off-Label Promotion Policy 29:23

18d ago29:23

29:23

Pink Sheet Executive Editor Derrick Gingery, Senior Writer Sarah Karlin-Smith and Editor-in-Chief Nielsen Hobbs discuss the reasons US Food and Drug Administration Commissioner Martin Makary could have helped negotiate the Most Favored Nation drug pricing deal with Astra Zeneca (:30) and the deal’s potential impact on the 340B program (16:35). They…

1
Unpacking the FDA transparency push on CRLs 22:33

18d ago22:33

22:33

The FDA made waves in early September when it announced a plan to publicly release complete response letters (CRLs) at the same time they are issued to sponsoring companies, part of what the agency calls a push toward “radical transparency.” At the same time, the FDA released 89 new CRLs, adding to the more than 200 that were previously made public…

1
Adalvo: Exploring European B2B Pharma’s Next Steps 14:41

18d ago14:41

14:41

Adalvo: Exploring European B2B Pharma’s Next Steps by CitelineBy Citeline

1
Biotech Breakthroughs: Partnerships, AI, and Clinical Triumphs 9:40

19d ago9:40

9:40

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're delving into a series of fascinating updates that underscore a period of significant scientific advancement, strategic partnerships, and regulatory developments in the industry.Starting with Dianthus Ther…

1
Biotech royalty deals on the rise and here to stay 51:18

18d ago51:18

51:18

In today's episode, we welcome Clarke Futch, Chairman and CEO of HealthCare Royalty Partners, or HCRx. HCRx are pioneers in royalty-based financing, with a thirty year track record in biopharma investing. Clarke has led more than 60 royalty acquisitions totaling nearly $4 billion and raised over $8 billion across various vehicles, executing more th…

1
Lupus Clinical Development Enters a New Era of Innovation 35:32

19d ago35:32

35:32

Join host David Wild as he speaks with Stacie Bell, chief clinical research officer at Lupus Therapeutics, about the dramatic transformation happening in lupus drug development. From a field once avoided by pharma companies to one generating unprecedented excitement, Bell discusses how her organization's 62-center network is revolutionizing clinica…

1
374: Veteran biotech executive Clive Meanwell on drug pricing and the obesity market 34:10

20d ago34:10

34:10

On this week’s episode of “The Readout LOUD”: an interview with veteran biotech executive and company founder Clive Meanwell. Pfizer recently acquired one of Meanwell’s companies, the obesity drug developer Metsera, for just under $5 billion. Meanwell offered his perspectives on the evolving obesity drug market, and continued need for drugs to trea…

Pharma And BioTech News Podcasts